secwatch.observer — SEC 8-K summary
======================================

Issuer:     Decoy Therapeutics Inc. (DCOY)
CIK:        0001615219
Form:       8-K
Filed at:   2023-08-10T23:59:59+00:00
Accession:  0001615219-23-000063
Event type: other_material
Sentiment:  negative
Materiality: 0.90
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Salarius explores strategic alternatives, cuts workforce >50% after Q2 net loss of $3.9M
--------------------------------------------------------------------------------

- FDA removed partial clinical hold on seclidemstat Phase 1/2 Ewing sarcoma trial.
- SP-3164 received FDA IND clearance for relapsed/refractory NHL Phase 1 trial.
- Cash $11.5M as of June 30, expected to fund operations through Q4 2023.
- Net loss Q2 2023 was $3.9M ($1.43/share) vs $4.7M ($2.20/share) in Q2 2022.
- Implementing cost-savings plan with >50% workforce reduction to extend resources.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1615219/000161521923000063/0001615219-23-000063-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1615219/000161521923000063/flks-20230810.htm
  HTML page:      https://secwatch.observer/filing/0001615219-23-000063

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer